Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$5.35
-1.3%		$8.52
$5.04
▼
$25.95
$248.76M1.08907,593 shs811,315 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.83
+1.7%		$2.25
$1.33
▼
$2.61
$251.16M0.89715,436 shs400,740 shs
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$1.54
+4.1%		$1.83
$1.32
▼
$2.86
$257.92M1.613.44 million shs1.82 million shs
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
$1.02
+3.0%		$1.45
$0.78
▼
$99.75
$51.23M-0.0738.25 million shs17.03 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-2.69%-13.42%-36.08%-75.54%-1.63%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+2.27%-7.22%-24.69%-10.45%+11.11%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
+1.02%0.00%-27.80%-21.69%-20.00%
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
-20.80%-64.39%+11.89%-20.16%-81.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$5.35
-1.3%		$8.52
$5.04
▼
$25.95
$248.76M1.08907,593 shs811,315 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.83
+1.7%		$2.25
$1.33
▼
$2.61
$251.16M0.89715,436 shs400,740 shs
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$1.54
+4.1%		$1.83
$1.32
▼
$2.86
$257.92M1.613.44 million shs1.82 million shs
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
$1.02
+3.0%		$1.45
$0.78
▼
$99.75
$51.23M-0.0738.25 million shs17.03 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-2.69%-13.42%-36.08%-75.54%-1.63%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+2.27%-7.22%-24.69%-10.45%+11.11%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
+1.02%0.00%-27.80%-21.69%-20.00%
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
-20.80%-64.39%+11.89%-20.16%-81.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
2.63
Moderate Buy$33.00516.82% Upside
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.90
Moderate Buy$4.75159.56% Upside
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
3.00
Buy$9.29502.97% Upside
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SDEV, BIOA, PALI, and IKT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price TargetNeutral$1.50
10/13/2026
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageHold$1.50
10/13/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$7.00
10/12/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageNeutral$8.00
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
10/8/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$6.00
10/8/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/8/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$6.00
9/23/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$7.00
9/9/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$25.00
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$8.99M27.32N/AN/A$7.59 per share0.70
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$260K982.15N/AN/A$2.30 per share0.80
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$250K1,073.50N/AN/A$0.87 per share1.77
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
$9.78M5.40N/AN/A($0.92) per share-1.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$80.61M-$2.38N/AN/AN/A-912.26%-28.99%-27.09%N/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$48.26M-$0.43N/AN/AN/AN/A-42.80%-40.58%N/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$16.78M-$0.48N/AN/AN/AN/A-33.47%-31.79%11/9/2026 (Estimated)
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
-$22.14M-$9.95N/AN/AN/AN/A-17.06%-12.81%N/A

Latest SDEV, BIOA, PALI, and IKT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$0.06N/AN/AN/A$0.47 millionN/A
8/11/2026Q2 2026
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$0.09-$0.11-$0.02-$0.11N/AN/A
8/10/2026Q2 2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$0.0522-$0.05+$0.0022-$0.05$0.50 million$0.50 million
8/5/2026Q2 2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$0.65-$0.58+$0.07-$0.58N/A$2.45 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/AN/AN/AN/AN/A
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
17.19
17.19
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
15.82
15.82
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/A
24.26
24.26
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
N/A
29.98
29.98

Institutional Ownership

CompanyInstitutional Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
11.79%
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
23.25%

Insider Ownership

CompanyInsider Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
17.55%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.10%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
0.07%
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
43.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
6245.90 million37.84 millionN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
35139.54 million129.63 millionN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
14174.27 million174.15 millionNot Optionable
Stablecoin Development Corporation stock logo
SDEV
Stablecoin Development
3051.75 million29.08 millionNot Optionable

Recent News About These Companies

Stablecoin Development Corporation (NYSEAMERICAN:SDEV) Sees Large Increase in Short Interest
October 12 at 9:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110581
Stablecoin Development Corp (Derivatives) Price Today in India
October 6, 2026  |  goodreturns.inG
Fugazi Research calls Stablecoin Development Corporation stock uninvestable
October 5, 2026  |  cryptobriefing.comC
Stablecoin Development Corporation Announces 2026 Annual Meeting and Key Proposals
September 30, 2026  |  kalkinemedia.comK
Azioni Stablecoin Development sfiorano 1,79$, poi il rifiuto le riporta a 1,57$
September 29, 2026  |  cryptonomist.chC
Stablecoin Development Addresses Recent Unusual Stock Trading Activity
September 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/stablecoin-development-addresses-recent-unusual-stock-trading-activity?utm_source=marketbeat.com&utm_medium=referral
Stablecoin Development Stock Skyrockets Tuesday: What's Happening?
September 29, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/62063119/stablecoin-development-stock-skyrockets-tuesday-whats-happening?utm_source=snapi
Why Stablecoin Development Corporation’s (SDEV) Stock Is Up 10.24%
September 22, 2026  |  aaii.comA
Stablecoin grows as more countries explore sovereign tokens
September 11, 2026  |  coingeek.comC
Stablecoin Development Corporat (SDEV)
September 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SDEV/holders/
Stablecoin Development Corporation : SDEV
August 25, 2026  |  247wallst.comhttps://247wallst.com/companies/sdev/
SDEV - Stablecoin Development Corporation
August 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/SDEV/historical-price-quotes
Stablecoin Development Corp.
August 6, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/sdev/stock-grader
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338010/0/en/sdev-abbott-cooper-pllc-announces-investigation-on-behalf-of-stablecoin-development-corporation-formerly-novabay-pharmaceuticals-inc-stockholders.html
Crypto company relocates headquarters from California
August 3, 2026  |  bizjournals.comhttps://www.bizjournals.com/southflorida/news/2026/08/03/stablecoin-dev-corp-west-palm-beach-hq.html
Emeryville crypto company relocates headquarters to Florida
August 3, 2026  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2026/08/03/stablecoin-dev-corp-west-palm-beach-emeryville.html
SDEV 스카이 수익 30억원…평가손 700억원
August 1, 2026  |  tokenpost.krT
Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336791/0/en/stablecoin-development-corporation-reports-second-quarter-2026-financial-results.html
Stablecoin Development Stock Short Interest Report | AMEX:SDEV | Benzinga
July 20, 2026  |  benzinga.comhttps://www.benzinga.com/quote/SDEV/short-interest
Stablecoin Development Names Henry Blynn as New COO
July 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/stablecoin-development-names-henry-blynn-as-new-coo?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAge Labs stock logo

BioAge Labs NASDAQ:BIOA

$5.35 -0.07 (-1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$5.31 -0.04 (-0.82%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NASDAQ:IKT

$1.83 +0.03 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$1.80 -0.03 (-1.80%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Palisade Bio stock logo

Palisade Bio NASDAQ:PALI

$1.54 +0.06 (+4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.55 +0.01 (+0.58%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Stablecoin Development stock logo

Stablecoin Development NYSEAMERICAN:SDEV

$1.02 +0.03 (+3.03%)
As of 04:10 PM Eastern

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas